PMID- 29496022
OWN - NLM
STAT- MEDLINE
DCOM- 20191118
LR  - 20191118
IS  - 2213-1787 (Electronic)
IS  - 2213-1779 (Linking)
VI  - 6
IP  - 3
DP  - 2018 Mar
TI  - Clinical Characteristics and Outcome of Methamphetamine-Associated Pulmonary 
      Arterial Hypertension and Dilated Cardiomyopathy.
PG  - 209-218
LID - S2213-1779(17)30692-3 [pii]
LID - 10.1016/j.jchf.2017.10.006 [doi]
AB  - OBJECTIVES: This study sought to characterize patients with 
      methamphetamine-associated pulmonary arterial hypertension (MA-PAH) and 
      cardiomyopathy (MA-CMP), to compare with MA controls (MA-CTL), users with 
      structurally normal hearts, with the aim of identifying risk factors for these 
      conditions. BACKGROUND: MA-PAH and MA-CMP are 2 poorly understood cardiac 
      complications in MA users. METHODS: We retrospectively studied the clinical 
      characteristics and outcomes of 50 MA-PAH, 296 MA-CMP, and 356 MA-CTL patients, 
      whom we evaluated between 2010 and 2017. RESULTS: After a median follow-up of 
      20.0 months (interquartile range [IQR]: 7.6 to 42.6 months), all-cause mortality 
      was 18.0% for MA-PAH, 15.2% for MA-CMP, and 4.5% for MA-CTL group (p < 0.001). 
      More women (58%) were in the MA-PAH group than in the MA-CMP (14%; p < 0.001) and 
      MA-CTL (42%; p = 0.028) groups, whereas the MA-CMP group was predominantly male 
      (86% vs. 58% in the MA-CTL group; p < 0.001). More MA-CMP patients had 
      hypertension (p < 0.001) or alcoholism (p < 0.001) than MA-CTL patients. Logistic 
      regression analyses identified male sex, alcoholism, and hypertension as 
      independent factors associated with MA-CMP with the following respective 
      adjusted odds ratios (OR) of 3.791 (95% confidence interval [CI]: 2.508 to 
      5.730), OR of 2.959 (95% CI: 2.084 to 4.203), and OR of 2.111 (95% CI: 1.486 to 
      2.999), whereas female sex was the only factor associated with MA-PAH. 
      CONCLUSIONS: Both MA-PAH and MA-CMP patients carried significant disease burden 
      and mortality risk. Male sex, hypertension, and alcoholism were strongly 
      associated with MA-CMP, whereas female sex and other unknown factors may 
      influence development of MA-PAH. This study adds to the understanding of 
      MA-associated cardiac complications and highlights directions for future 
      investigation.
CI  - Published by Elsevier Inc.
FAU - Zhao, Susan X
AU  - Zhao SX
AD  - Division of Cardiology, Santa Clara Valley Medical Center, San Jose, California. 
      Electronic address: susanxzhao@gmail.com.
FAU - Kwong, Calvin
AU  - Kwong C
AD  - Department of Medicine, Santa Clara Valley Medical Center, San Jose, California.
FAU - Swaminathan, Aravind
AU  - Swaminathan A
AD  - Division of Cardiology, Santa Clara Valley Medical Center, San Jose, California.
FAU - Gohil, Amit
AU  - Gohil A
AD  - Division of Pulmonary and Critical Care Medicine, Santa Clara Valley Medical 
      Center, San Jose, California.
FAU - Crawford, Michael H
AU  - Crawford MH
AD  - Division of Cardiology, University of California-San Francisco, San Francisco, 
      California.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - JACC Heart Fail
JT  - JACC. Heart failure
JID - 101598241
RN  - 0 (Central Nervous System Stimulants)
RN  - 44RAL3456C (Methamphetamine)
SB  - IM
CIN - JACC Heart Fail. 2018 Mar;6(3):219-221. PMID: 29496023
MH  - Adult
MH  - Alcoholism/complications/epidemiology
MH  - Amphetamine-Related Disorders/*complications/epidemiology
MH  - California/epidemiology
MH  - Cardiomyopathy, Dilated/*chemically induced/epidemiology
MH  - Case-Control Studies
MH  - Central Nervous System Stimulants/*adverse effects
MH  - Female
MH  - Humans
MH  - Hypertension, Pulmonary/*chemically induced/epidemiology
MH  - Male
MH  - Methamphetamine/*adverse effects
MH  - Middle Aged
MH  - Prevalence
MH  - Retrospective Studies
MH  - Sex Distribution
OTO - NOTNLM
OT  - dilated cardiomyopathy
OT  - heart failure
OT  - methamphetamine
OT  - pulmonary arterial hypertension
EDAT- 2018/03/03 06:00
MHDA- 2019/11/19 06:00
CRDT- 2018/03/03 06:00
PHST- 2017/08/14 00:00 [received]
PHST- 2017/10/05 00:00 [revised]
PHST- 2017/10/07 00:00 [accepted]
PHST- 2018/03/03 06:00 [entrez]
PHST- 2018/03/03 06:00 [pubmed]
PHST- 2019/11/19 06:00 [medline]
AID - S2213-1779(17)30692-3 [pii]
AID - 10.1016/j.jchf.2017.10.006 [doi]
PST - ppublish
SO  - JACC Heart Fail. 2018 Mar;6(3):209-218. doi: 10.1016/j.jchf.2017.10.006.